Increased dietary fat promotes islet amyloid formation and β-cell secretory dysfunction in a transgenic mouse model of islet amyloid

Diabetes

Volumn 52, Issue 2, 2003, Pages 372-379

  Hull, Rebecca L ^a,b   Andrikopoulos, Sofianos ^a   Verchere, C Bruce ^a   Vidal, Josep ^a   Wang, Feng ^a   Cnop, Miriam ^a   Prigeon, Ronald L ^a   Kahn, Steven E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COMPOSITION; CELL FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; ENDOCRINE CELL; FAT INTAKE; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PATHOGENESIS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

AMYLOID; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIETARY FATS; GLUCAGON; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MICE, TRANSGENIC; PANCREATIC POLYPEPTIDE; SOMATOSTATIN;

EID: 0037315790     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.2.372     Document Type: Article

References (60)

1. Reaven GM: Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
2. Pi-Sunyer FX: Medical hazards of obesity. Ann Intern Med 119:655-660, 1993
3. Marshall JA, Hoag S, Shetterly S, Hamman RF: Dietary fat predicts conversion from impaired glucose tolerance to NIDDM: the San Luis Valley Diabetes Study. Diabetes Care 17:50-56, 1994
4. Storlien LH, James DE, Burleigh KM, Chisholm DJ, Kraegen EW: Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol 251:E576-E583, 1986
5. Rocchini AP, Marker P, Cervenka T: Time course of insulin resistance associated with feeding dogs a high-fat diet. Am J Physiol 272:E147-E154, 1997
6. Westermark P: Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77:91-94, 1972
7. Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC: Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285-289, 1990
8. Westermark P: Amyloid and polypeptide hormones: what is their interrelationship? (Review) Amyloid-Int J Exp Clin Invest 1:47-60, 1994
9. Howard CF Jr: Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29:301-306, 1986
10. Soeller WC, Janson J, Hart SE, Parker JC, Carty MD, Stevenson RW, Kreutter DK, Butler PC: Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. Diabetes 47:743-750, 1998
11. Hoppener JWM, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JHH, Vroom TM, Ahren B, Lips CJM: Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: Pathogenesis of diabetes in a mouse model. Diabetologia 42:427-434, 1999
12. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulmoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 84:3881-3885, 1987
13. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84:8628-8632, 1987
14. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036-5040, 1990
15. Fox N, Schrementi J, Nishi M, Ohagi S, Chan SJ, Heisserman JA, Westermark GT, Leckstrom A, Westermark P, Steiner DF: Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes-mellitus (NIDDM). FEBS Lett 323:40-44, 1993
16. Hoppener JWM, Verbeek JS, Dekoning EJP, Oosterwijk C, Vanhulst KL, Visservernooy HJ, Hofhuis FMA, Vangaalen S, Berends MJH, Hackeng WHL, Jansz HS, Morris JF, Clark A, Capel PJA, Lips CJM: Chronic overproduction of islet amyloid polypeptide (amylin) in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycemia or hyperinsulinemia. Diabetologia 36:1258-1265, 1993
17. D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD, Ensinck JW: Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457-1461, 1994
18. Yagui K, Yamaguchi T, Kanatsuka A, Shimada F, Huang CI, Tokuyama Y, Ohsawa H, Yamamura KI, Miyazaki JI, Mikata A, Yoshida S, Makino H: Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide (amylin). Eur J Endocrinol 132:487-496, 1995
19. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC: Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:7283-7288, 1996
20. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE: Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:3492-3496, 1996
21. Andrikopoulos S, Verchere CB, Terauchi Y, Kadowaki T, Kahn SE: β-Cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes 49: 2056-2062, 2000
22. Morgan DR, Lazarow A: Immunoassay of insulin: two antibody system: Plasma insulin levels of normal, subdiabetic, and diabetic rats. Diabetes 12:115-126, 1963
23. Percy AJ, Trainor DA, Rittenhouse J, Phelps J, Koda JE: Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 42:576-585, 1996
24. Wang F, Hull RL, Vidal J, Cnop M, Kahn SE: Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:2514-2520, 2001
25. Jonchkeere AR: A distribution-free $k$-sample test against ordered alternatives. Biometrika 41:133-145, 1954
26. Kahn SE, Andrikopoulos S, Verchere CB, Wang F, Hull RL, Vidal J: Oophorectomy promotes islet amyloid formation in a transgenic mouse model of type II diabetes. Diabetologia 43:1309-1312, 2000
27. Lee SK, Opara EC, Surwit RS, Feinglos MN, Akwari OE: Defective glucose-stimulated insulin release from perifused islets of C57BL/6J mice. Pancreas 11:206-211, 1995
28. Ludwig DS, Tritos NA, Mastaitis JW, Kulkarni R, Kokkotou E, Elmquist J, Lowell B, Flier JS, Maratos-Flier E: Melanin-concentrating hormone over-expression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 107: 379-386, 2001
29. Westermark GT, Leckstrom A, Ma Z, Westermark P: Increased release of LAPP in response to long-term high fat intake in mice. Horm Metab Res 30:256-258, 1998
30. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:110-125, 1985
31. Gapp DA, Leiter EH, Coleman DL, Schwizer RW: Temporal changes in pancreatic islet composition in C57BL/6J-db/db (diabetes) mice. Diabetologia 25:439-443, 1983
32. Milburn JL Jr, Hirose H, Lee YH, Nagasawa Y, Ogawa A, Ohneda M, BeltrandelRio H, Newgard CB, Johnson JH, Unger RH: Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem 270:1295-1299, 1995
33. Mulder H, Martensson H, Sundler F, Ahren B: Differential changes in islet amyloid polypeptide (amylin): and insulin mRNA expression after high-fat diet-induced insulin resistance in C57BL/6J mice: Metabolism 49:1518-1522, 2000
34. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJS, Holman RR, Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type-2 diabetes. Diabetes Res Clin Exp 9:151-159, 1988
35. Kahn SE, Andrikopoulos S, Verchere CB: Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253, 1999
36. Kahn SE: The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058, 2001
37. Ahren B: Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand 171:161-167, 2001
38. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B: Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 282:E834-E842, 2002
39. Black BL, Croom J, Eisen EJ, Petro AE, Edwards CL, Surwit RS: Differential effects of fat and sucrose on body composition in A/J and C57BL/6 mice. Metabolism 47:1354-1359, 1998
40. Schreyer SA, Wilson DL, LeBoeuf RC: C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis 136:17-24, 1998
41. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC, Kuhn CM, Rebuffe-Scrive M: Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44:645-651, 1995
42. Pacini G, Thomaseth K, Ahren B: Contribution to glucose tolerance of insulin-independent vs. insulin-dependent mechanisms in mice. Am J Physiol Endocrinol Metab 281:E693-E703, 2001
43. Gedulin B, Cooper GJS, Young AA: Amylin secretion from the perfused pancreas: dissociation from insulin and abnormal elevation in insulin-resistant diabetic rats. Biochem Biophys Res Comm 180:782-789, 1991
44. Brethertonwatt D, Ghatei MA, Bloom SR, Jamal H, Ferrier GJM, Girgis SI, Legon S: Altered islet amyloid polypeptide (amylin) gene-expression in rat models of diabetes. Diabetologia 32:881-883, 1989
45. O'Brien TD, Westermark P, Johnson KH: Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes 40:1701-1706, 1991
46. Ludvik B, Clodi M, Kautzkywiller A, Capek M, Hartter E, Pacini G, Prager R: Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin-secretion in humans. Diabetologia 36:84-87, 1993
47. Bjorklund A, Grill V: Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets. Diabetes 48:1409-1414, 1999
48. Porte D Jr, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM: Clues to etiology of islet β-cell dysfunction? Diabetes 38:1333-1336, 1989
49. Zhou YP, Grill VE: Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93:870-876, 1994
50. Bollheimer LC, Skelly RH, Chester MW, McGarry JD, Rhodes CJ: Chronic exposure to free fatty acid reduces pancreatic beta cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis translation. J Clin Invest 101:1094-1101, 1998
51. Furukawa H, Carroll RJ, Swift HH, Steiner DF: Long-term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic β-cell line MIN6. Diabetes 48:1395-1401, 1999
52. Badman MK, Shennan KIJ, Jermany JL, Docherty K, Clark A: Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 378:227-231, 1996
53. Higham CE, Hull RL, Lawrie L, Shennan KI, Morris JF, Birch NP, Docherty K, Clark A: Processing of synthetic pro-islet amyloid polypeptide (proIAPP) 'amylin' by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 267:4998-5004, 2000
54. Wang J, Xu J, Finnerty J, Furuta M, Steiner DF, Verchere CB: The prohormone convertase enzyme 2 (PC2) is essential for processing proislet amyloid polypeptide at the NH2-terminal cleavage site. Diabetes 50:534-539, 2001
55. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491-498, 1999
56. Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type 2 diabetes mellitus. Nature 368:756-760, 1994
57. Zhang S, Liu J, Saafi EL, Cooper GJ: Induction of apoptosis by human amylin in RINm5F islet beta-cells is associated with enhanced expression of p53 and p21WAF1/CIP1. FEBS Lett 455:315-320, 1999
58. Anguiano M, Nowak RJ, Lansbury PTJ: Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41:11338-11343, 2002
59. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-1200, 2001
60. Bray GA, Popkin BM: Dietary fat intake does affect obesity! Am J Clin Nutr 68:1157-1173, 1998